Back to discover
Drug

Lanreotide

In clinical development
Emerging researchLate-stage development

Also known as Somatuline, Lanreotida.

RxNorm68092ChEMBLCHEMBL1201185ATCH01CB03UNII0G3DE8943Y
2
Research papers
4
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)

Clinical trial2026-04-09Results expected Q3 2027 · ClinicalTrials.gov

A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Clinical trial2026-03-31Results expected Q4 2027 · ClinicalTrials.gov

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Clinical trial2026-03-30Results expected Q4 2026 · ClinicalTrials.gov

Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)

Clinical trial2026-03-02Results expected Q1 2027 · ClinicalTrials.gov

Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Clinical trial2025-03-05Results posted · ClinicalTrials.gov

A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial

Clinical trial2023-11-01Primary completion · ClinicalTrials.gov

Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Clinical trial2023-06-29Results posted · ClinicalTrials.gov

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

Clinical trial2022-10-14Results posted · ClinicalTrials.gov

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Clinical trial2022-10-12Results posted · ClinicalTrials.gov

Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone

Clinical trial2022-09-27Results posted · ClinicalTrials.gov

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Research2016-05-23Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Research2014-07-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lanreotide
Aliases & brands
SomatulineLanreotida
RxNorm CUI
68092
ChEMBL ID
CHEMBL1201185
ATC codes
H01CB03
UNII
0G3DE8943Y

Clinical trials

36 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
36
registered trials across all phases
LATEST COMPLETION 2022
4
Active studies
3
Recruiting
23
Late-stage (III+)
18
Completed
14
Discontinued
PHASE DISTRIBUTIONn = 36
Phase 1 / 22Phase 211Phase 2 / 35Phase 312Phase 45Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

PILOT STUDY OF LANREOTIDE IN METASTATIC OR RECURRENT GRADE I-II HINDGUT NET

Unknown statusPH IVSamsung Medical Centern=282020

A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity

TerminatedPH IVSaint John's Cancer Instituten=42016

A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.

CompletedPH IVIpsenn=262010

A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR

CompletedPH IVIpsenn=82006

A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel.

CompletedPH IVIpsenn=302005

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

CompletedPH I/IIDuke Universityn=222022

Lanreotide In Polycystic Kidney Disease Study

CompletedPH IIIAssistance Publique - Hôpitaux de Parisn=1592019

A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants

CompletedPH IINorthwell Healthn=122019

Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II.

CompletedPH IIUniversity Hospital, Grenoblen=352017

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

CompletedPH IIIIpsenn=1152015

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

CompletedPH IIIIpsenn=892015

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20142016
Most influential

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

The New England journal of medicine · 2014 · 1,240 cites

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016 · 69 cites
Recent papers

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016 · 69 cites

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

The New England journal of medicine · 2014 · 1,240 cites
Journals, researchers & institutions
Top journals
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1
  • The New England journal of medicine1
Leading researchers
  • Wolin EM2
  • Blumberg J1
  • Cadiot G1
  • Capdevila J1
  • Caplin ME1
  • Ćwikła JB1
  • Fisher GA1
  • Gomez-Panzani E1
Leading institutions
free-text, unnormalised
  • From Royal Free Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials